vs
Side-by-side financial comparison of Protagonist Therapeutics, Inc (PTGX) and Walker & Dunlop, Inc. (WD). Click either name above to swap in a different company.
Walker & Dunlop, Inc. is the larger business by last-quarter revenue ($340.0M vs $170.6M, roughly 2.0× Protagonist Therapeutics, Inc). Protagonist Therapeutics, Inc runs the higher net margin — 77.2% vs -12.9%, a 90.1% gap on every dollar of revenue. On growth, Protagonist Therapeutics, Inc posted the faster year-over-year revenue change (184.4% vs -0.4%). Protagonist Therapeutics, Inc produced more free cash flow last quarter ($182.8M vs $-680.1M).
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel peptide-based targeted therapies for unmet medical needs, primarily covering gastrointestinal disorders, inflammatory diseases and rare disease indications. Its lead product candidates target inflammatory bowel disease and other chronic immune-related conditions, with operations spanning global R&D and partnership collaborations.
Walker & Dunlop, Inc. is one of the largest commercial real estate finance and advisory services firms in the United States and internationally.
PTGX vs WD — Head-to-Head
Income Statement — Q4 FY2024 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $170.6M | $340.0M |
| Net Profit | $131.7M | $-13.9M |
| Gross Margin | — | — |
| Operating Margin | 74.3% | -17.2% |
| Net Margin | 77.2% | -12.9% |
| Revenue YoY | 184.4% | -0.4% |
| Net Profit YoY | 381.7% | -131.0% |
| EPS (diluted) | $2.01 | $-0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $340.0M | ||
| Q3 25 | — | $337.7M | ||
| Q2 25 | — | $319.2M | ||
| Q1 25 | — | $237.4M | ||
| Q4 24 | $170.6M | $341.5M | ||
| Q3 24 | — | $292.3M | ||
| Q2 24 | — | $270.7M | ||
| Q1 24 | $255.0M | $228.1M |
| Q4 25 | — | $-13.9M | ||
| Q3 25 | — | $33.5M | ||
| Q2 25 | — | $34.0M | ||
| Q1 25 | — | $2.8M | ||
| Q4 24 | $131.7M | $44.8M | ||
| Q3 24 | — | $28.8M | ||
| Q2 24 | — | $22.7M | ||
| Q1 24 | $207.3M | $11.9M |
| Q4 25 | — | -17.2% | ||
| Q3 25 | — | 13.6% | ||
| Q2 25 | — | 14.5% | ||
| Q1 25 | — | 2.2% | ||
| Q4 24 | 74.3% | 15.3% | ||
| Q3 24 | — | 12.8% | ||
| Q2 24 | — | 10.4% | ||
| Q1 24 | 80.9% | 6.0% |
| Q4 25 | — | -12.9% | ||
| Q3 25 | — | 9.9% | ||
| Q2 25 | — | 10.6% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | 77.2% | 13.1% | ||
| Q3 24 | — | 9.9% | ||
| Q2 24 | — | 8.4% | ||
| Q1 24 | 81.3% | 5.2% |
| Q4 25 | — | $-0.41 | ||
| Q3 25 | — | $0.98 | ||
| Q2 25 | — | $0.99 | ||
| Q1 25 | — | $0.08 | ||
| Q4 24 | $2.01 | $1.32 | ||
| Q3 24 | — | $0.85 | ||
| Q2 24 | — | $0.67 | ||
| Q1 24 | $3.26 | $0.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $418.9M | $299.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $675.3M | $1.7B |
| Total Assets | $744.7M | $5.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $299.3M | ||
| Q3 25 | — | $274.8M | ||
| Q2 25 | — | $233.7M | ||
| Q1 25 | — | $181.0M | ||
| Q4 24 | $418.9M | $279.3M | ||
| Q3 24 | — | $179.8M | ||
| Q2 24 | — | $208.1M | ||
| Q1 24 | $322.6M | $216.5M |
| Q4 25 | — | $1.7B | ||
| Q3 25 | — | $1.8B | ||
| Q2 25 | — | $1.8B | ||
| Q1 25 | — | $1.7B | ||
| Q4 24 | $675.3M | $1.7B | ||
| Q3 24 | — | $1.7B | ||
| Q2 24 | — | $1.7B | ||
| Q1 24 | $560.4M | $1.7B |
| Q4 25 | — | $5.1B | ||
| Q3 25 | — | $5.8B | ||
| Q2 25 | — | $4.7B | ||
| Q1 25 | — | $4.5B | ||
| Q4 24 | $744.7M | $4.4B | ||
| Q3 24 | — | $4.6B | ||
| Q2 24 | — | $4.2B | ||
| Q1 24 | $629.3M | $3.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $184.2M | $-664.3M |
| Free Cash FlowOCF − Capex | $182.8M | $-680.1M |
| FCF MarginFCF / Revenue | 107.1% | -200.0% |
| Capex IntensityCapex / Revenue | 0.8% | 4.6% |
| Cash ConversionOCF / Net Profit | 1.40× | — |
| TTM Free Cash FlowTrailing 4 quarters | $101.7M | $-2.2B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-664.3M | ||
| Q3 25 | — | $-948.1M | ||
| Q2 25 | — | $-238.5M | ||
| Q1 25 | — | $-281.1M | ||
| Q4 24 | $184.2M | $129.4M | ||
| Q3 24 | — | $-202.0M | ||
| Q2 24 | — | $-237.8M | ||
| Q1 24 | $-27.4M | $38.4M |
| Q4 25 | — | $-680.1M | ||
| Q3 25 | — | $-950.4M | ||
| Q2 25 | — | $-241.0M | ||
| Q1 25 | — | $-284.7M | ||
| Q4 24 | $182.8M | $116.4M | ||
| Q3 24 | — | $-204.0M | ||
| Q2 24 | — | $-241.7M | ||
| Q1 24 | $-27.7M | $35.2M |
| Q4 25 | — | -200.0% | ||
| Q3 25 | — | -281.5% | ||
| Q2 25 | — | -75.5% | ||
| Q1 25 | — | -120.0% | ||
| Q4 24 | 107.1% | 34.1% | ||
| Q3 24 | — | -69.8% | ||
| Q2 24 | — | -89.3% | ||
| Q1 24 | -10.9% | 15.4% |
| Q4 25 | — | 4.6% | ||
| Q3 25 | — | 0.7% | ||
| Q2 25 | — | 0.8% | ||
| Q1 25 | — | 1.5% | ||
| Q4 24 | 0.8% | 3.8% | ||
| Q3 24 | — | 0.7% | ||
| Q2 24 | — | 1.4% | ||
| Q1 24 | 0.1% | 1.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | -28.34× | ||
| Q2 25 | — | -7.02× | ||
| Q1 25 | — | -102.07× | ||
| Q4 24 | 1.40× | 2.89× | ||
| Q3 24 | — | -7.01× | ||
| Q2 24 | — | -10.49× | ||
| Q1 24 | -0.13× | 3.24× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
